- Home
- URGN vs BBNX Comparison
URGN vs BBNX Comparison
Compare URGN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- BBNX
- Stock Information
- Founded
- URGN 2004
- BBNX 2015
- Country
- URGN United States
- BBNX United States
- Employees
- URGN N/A
- BBNX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- URGN Health Care
- BBNX Health Care
- Exchange
- URGN Nasdaq
- BBNX Nasdaq
- Market Cap
- URGN 904.0M
- BBNX 740.7M
- IPO Year
- URGN 2017
- BBNX 2025
- Fundamental
- Price
- URGN $18.94
- BBNX $26.33
- Analyst Decision
- URGN Strong Buy
- BBNX Strong Buy
- Analyst Count
- URGN 8
- BBNX 10
- Target Price
- URGN $28.50
- BBNX $24.40
- AVG Volume (30 Days)
- URGN 1.1M
- BBNX 653.2K
- Earning Date
- URGN 11-05-2025
- BBNX 11-06-2025
- Dividend Yield
- URGN N/A
- BBNX N/A
- EPS Growth
- URGN N/A
- BBNX N/A
- EPS
- URGN N/A
- BBNX N/A
- Revenue
- URGN $94,238,000.00
- BBNX $69,830,000.00
- Revenue This Year
- URGN $35.60
- BBNX $42.80
- Revenue Next Year
- URGN $129.54
- BBNX $34.58
- P/E Ratio
- URGN N/A
- BBNX N/A
- Revenue Growth
- URGN 10.85
- BBNX 38911.17
- 52 Week Low
- URGN $3.42
- BBNX $8.89
- 52 Week High
- URGN $21.71
- BBNX $25.63
- Technical
- Relative Strength Index (RSI)
- URGN 49.18
- BBNX 84.85
- Support Level
- URGN $18.45
- BBNX $18.12
- Resistance Level
- URGN $21.71
- BBNX $19.32
- Average True Range (ATR)
- URGN 1.18
- BBNX 1.32
- MACD
- URGN -0.17
- BBNX 0.73
- Stochastic Oscillator
- URGN 20.90
- BBNX 99.14
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.